Baisong Mei: Thanks, Greg, for the question. Absolutely, we received very positive feedback from our investigators as well as patient community. From investigators, they’re really to see grad to see the consistency of our results and the normalization of the total hemoglobin. And I actually asked a specific point question to one of our investigators how do you feel the normalization of [indiscernible] and with the value he will say, — that’s absolutely very important and his own patient that already told him about the energy that the patient has and the different they have and their life change in there, too. So that’s [indiscernible] clinical observation and patient likewise perspective. And related to the data from patient community perspective, — after the June presentation, our volume of patient inquiries increased 10x over that period of time after the presentation.
So we’re very pleased on that too. And we continue to see receiving queries not only in U.S. but also Canada and we’ll help them to moving through and understand the trial and find the visibility whether they can join us enough. So very, very good.
Greg Harrison: Great to hear the progress.
Baisong Mei: Thank you, Greg.
Operator: Our next question comes from Joon Lee from Truist Securities.
Joon Lee: Congrats on the progress. Your cash guidance into the third quarter of ’20 is pretty specific. What’s baked into that guidance? Specifically, does that include preclinical and IND-enabling studies of in vivo programs and/or BLA and pre-commercial activities for EDIT-301. In fact, is it your intention to commercialize E-301 yourself? Or would you be looking to a partner to help you with the heavy lifting on the commercial offer?
Gilmore O’Neill: So I think, Jim, I’ll let Eric start.
Erick Lucera: Yes, with respect to the specific dollars that are included into the cash runway guidance. We were including all of the BLA activities and everything we need to do to prepare for that within the guidance. With respect to IND-enabling studies, we do have some early preclinical research amount in that and we’ll see what Linda comes up with in the future as to whether or not we reallocate some dollars from other programs or not. But that’s where we are at this point with respect to guidance in terms of commercialization for the partner.
Gilmore O’Neill: Yes, Joon. We actually see commercialization as a nice upside, particularly for making sure we expand our global footprint. And we previously stated that we certainly want to partner ex U.S. Obviously, as we talk to partners or potential partners, if the terms really line up with where we are to ensure that we can maximize value for patients, shareholders, we could consider co-commercialization in addition to global to development and commercialization in the United States.
Operator: Our next question comes from Gena Wang with Barclays.
Gena Wang: Two very quick questions. Regarding the in vivo target, is it fair to say it will be a liver targeted and with particle [ph] delivery? And then regarding the manufacturing, just follow-up. So you do have a so facility. And what is your plan for commercial manufacturing capacity in the future? Will you wholly sit in the U.S. try to do a wholly in-house? Or would you plan to also collaborate with the CDMO regarding the manufacturing commercial supply?
Gilmore O’Neill: Thanks very much, Gina. With regard to the in vivo targets, obviously, we’ve talked about hematopoietic stem cells of an area of particular interest because of our 301 work and the human validation or ASCs 12a and gamma globin promoter. The liver is definitely on our list of potential tissues at [indiscernible] stem cells. And I think you can reasonably infer with the cessation of our activities of AAV that we’re interested in non-AAV technologies and LNPs is certainly an area of interest and one that we have been working on in the past and actually talked about working on over the past year plus. With regard to manufacturing, thanks for asking about that. We actually — with the announcement of our Azure deal, this is essentially enables us to build towards our commercial capacity and readiness for launch.
With regard to the more specific elements of around capacity and our prediction, that’s something that we are working through and would talk about in the future.
Operator: Our next question comes from Dae Gon Ha with Stifel.
